VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases
Authors:
Open Access
- 20 January 2023
- journal article
- review article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 18 (3) , 711-722
Abstract
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described pathological entity. It is an acquired monogenic autoinflammatory disease caused by somatic mutations of the UBA1 gene in blood cells precursors; the gene encodes one of the two E1 enzyme isoforms that initiates ubiquitylation in cell’s cytoplasm. VEXAS syndrome leads to systemic inflammation, with all organs and tissues potentially involved. The clinical picture may be extremely heterogenous, mimicking different other systemic rheumatologic entities coexisting with haematological disorders, especially myelodysplastic syndrome. This new disease represents a very intriguing clinical condition in several respects: it accounts for the paradigm of adult-onset monogenic autoinflammatory diseases determined by a genetic mosaicism resulting in the development of a challenging multiorgan inflammatory condition. Moreover, VEXAS syndrome is perhaps not an exceptionally rare condition and represents an example of a systemic genetic autoinflammatory disease drawing its origin in bone marrow disorders. VEXAS syndrome should be strongly considered in each adult patient with an unexplained systemic inflammatory condition, especially when recurrent fevers, neutrophilic dermatosis, relapsing polychondritis, ocular inflammation and other systemic inflammatory symptoms accompanying myelodysplastic syndrome or other haematological disorders. The syndrome deserves a multidisciplinary approach to reach the diagnosis and ensure the best management of a potentially very challenging condition. To quickly describe the clinical course, long-term outcomes, and the optimal management of this new syndrome it is essential to join forces internationally. To this end, the international AutoInflammatory Disease Alliance (AIDA) registry dedicated to VEXAS syndrome has been developed and is already active.Keywords
Funding Information
- Università degli Studi di Siena
This publication has 46 references indexed in Scilit:
- Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritisAnnals of the Rheumatic Diseases, 2021
- Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation SyndromeFrontiers in Immunology, 2021
- The VEXAS Syndrome: Uncontrolled Inflammation and Macrocytic Anaemia in a 77-Year-Old Male PatientEuropean Journal of Case Reports in Internal Medicine, 2021
- Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXASArthritis & Rheumatology, 2021
- Novel somatic mutations in UBA1 as a cause of VEXAS syndromeBlood, 2021
- VEXAS syndrome: still expanding the clinical phenotypeRheumatology, 2021
- Therapeutic options in VEXAS syndrome: insights from a retrospective seriesBlood, 2021
- Somatic mutations cause VEXAS syndromeNature Reviews Rheumatology, 2020
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020
- X inactivation analysis and DNA methylation studies of the ubiquitin activating enzyme E1 and PCTAIRE-1 genes in human and mouseHuman Molecular Genetics, 1996